In simple terms
Some breast cancers rely on oestrogen—a natural hormone in the body—to grow and multiply. Tamoxifen works by sitting in the receptors on breast cancer cells, acting like a key that fits into a lock but refuses to turn. Because the lock is blocked, your natural oestrogen cannot attach to the cell, which halts or slows down its growth. It is taken as a simple pill every day, usually for five to ten years, providing long-term protection against cancer recurrence.
Key takeaways
- Belongs to the drug class called selective oestrogen receptor modulators (SERMs).
- Taken as a once-daily oral tablet, typically for 5 to 10 years.
- Proven to cut the risk of ER-positive breast cancer recurrence by roughly half.
- Can cause menopausal-like symptoms such as hot flushes and night sweats.
- Carries small risks of thromboembolism and changes to the uterine lining.
Definition
Tamoxifen is a selective oestrogen receptor modulator (SERM) that exhibits both antagonistic and agonistic properties depending on the target tissue. In breast tissue, it competitively binds to oestrogen receptors, blocking endogenous oestrogen from stimulating cellular division in hormone-dependent malignancies.
Conversely, in bone and the endometrium, tamoxifen acts as a partial oestrogen agonist. It is widely indicated for adjuvant treatment in premenopausal and postmenopausal individuals with early-stage oestrogen receptor-positive (ER+) breast cancer, for metastatic disease, and as risk-reduction chemoprevention in individuals at high baseline risk of developing breast cancer.
Why it matters
For individuals diagnosed with hormone receptor-positive breast cancer, tamoxifen is one of the most effective risk-reducing therapies available. Adhering to the prescribed daily regimen markedly decreases the odds of cancer returning in the same breast, appearing in the opposite breast, or spreading elsewhere. Understanding its potential side effects—including hot flushes, mood changes, and rare risks such as blood clots or endometrial changes—allows patients to manage their daily wellbeing and communicate promptly with their clinical team.
Related biomarkers and tests
Before tamoxifen is offered, a tumour biopsy undergoes immunohistochemistry (IHC) testing to verify whether it expresses oestrogen receptors (ER) and progesterone receptors (PR). Routine baseline gynaecological assessments and occasional checks for drug interactions (such as CYP2D6-inhibiting antidepressants) may also be conducted.
Related cancers
Tamoxifen is predominantly prescribed for oestrogen receptor-positive (ER+) breast cancer across early, locally advanced, and metastatic settings. It is also used in ductal carcinoma in situ (DCIS) and occasionally prescribed off-label for select rare hormone-sensitive conditions, such as desmoid tumours or granulosa cell ovarian tumours.
Related treatments
Tamoxifen is usually initiated following primary surgical resection, radiation, or completion of cytotoxic chemotherapy. In premenopausal patients, it can be combined with ovarian function suppression (LHRH agonists) to achieve comprehensive hormonal control. Treatment duration typically spans five to ten consecutive years.
Frequently asked questions
Can premenopausal women take tamoxifen?
Yes. Unlike aromatase inhibitors, which are typically restricted to postmenopausal women, tamoxifen is effective and approved for both premenopausal and postmenopausal individuals diagnosed with hormone receptor-positive breast cancer.
What should I do if I experience hot flushes on tamoxifen?
Hot flushes are common. You should discuss them with your doctor, who can suggest practical lifestyle adjustments or prescribe non-hormonal medications to alleviate symptoms without interfering with tamoxifen's cancer-fighting mechanism.
Are there medications I should avoid while taking tamoxifen?
Yes. Certain antidepressants, particularly strong CYP2D6 inhibitors like fluoxetine and paroxetine, can reduce tamoxifen's conversion into its active form. Always inform your oncologist of all prescription drugs, herbal supplements, and over-the-counter products you take.
References
- 1.Tamoxifen: Drug Information— National Cancer Institute
- 2.Hormone Therapy for Breast Cancer— American Society of Clinical Oncology
- 3.ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients with Early Breast Cancer— European Society for Medical Oncology
Ask GetOnco AI
Get personalised answers about Tamoxifen — Hormone Therapy for Breast Cancer from your AI cancer care coordinator.
- Can you explain Tamoxifen — Hormone Therapy for Breast Cancer in simple words?
- What does Tamoxifen — Hormone Therapy for Breast Cancer mean for my treatment plan?
- What questions should I ask my oncologist about Tamoxifen — Hormone Therapy for Breast Cancer?
- What next steps do you recommend regarding Tamoxifen — Hormone Therapy for Breast Cancer?
GetOnco AI provides educational information and never replaces advice from your medical team.
Explore related topics
More in this section
Glossary terms in this article
Last reviewed August 1, 2026
Medical disclaimer
Educational information only. GetOnco is software, not a medical provider, and does not diagnose disease or recommend treatments. Always discuss your situation with qualified healthcare professionals.